Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: Results of an open-label, phase 1 study

Cancer Chemotherapy and Pharmacology

Volumn 76, Issue 5, 2015, Pages 1041-1049

  Tolcher, Anthony W ^a   Lorusso, Patricia ^b   Arzt, Jennifer ^c   Busman, Todd A ^c   Lian, Guinan ^c   Rudersdorf, Niki S ^c   Vanderwal, Carol Ann ^c   Waring, Jeffrey F ^c   Yang, Jianning ^c   Holen, Kyle D ^c   Rosen, Lee S ^d  

^a South Texas Accelerated Research Therapeutics (START)   (United States)

^b YALE CANCER CENTER   (United States)

^c ABBVIE INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bcl 2 inhibitor; Irinotecan; Navitoclax; Pharmacokinetic parameters; Safety

Indexed keywords

IRINOTECAN; NAVITOCLAX; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; PROTEIN BCL 2; SULFONAMIDE; TUMOR PROTEIN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CLINICAL ARTICLE; COLITIS; COLON CANCER; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DYSPHONIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOKALEMIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MERKEL CELL TUMOR; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OPEN STUDY; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PNEUMONIA; PRIORITY JOURNAL; RECTUM CANCER; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CHEMICALLY INDUCED; CLINICAL TRIAL; COLONIC NEOPLASMS; COMPARATIVE STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECTS; HEMATOLOGIC DISEASE; MIDDLE AGED; NEOPLASMS; PATHOLOGY; SALVAGE THERAPY; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANILINE COMPOUNDS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CAMPTOTHECIN; COLONIC NEOPLASMS; DIARRHEA; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC DISEASES; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SALVAGE THERAPY; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84944789659     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2882-9     Document Type: Article

References (26)

1. Davids MS, Letai A (2012) Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol 30(25):3127-3135
2. Leibowitz B, Yu J (2010) Mitochondrial signaling in cell death via the Bcl-2 family. Cancer Biol Ther 9(6):417-422
3. Schulze-Bergkamen H, Ehrenberg R, Hickmann L et al (2008) Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells. World J Gastroenterol 14(24):3829-3840
4. Verhaegen ME, Mangelberger D, Weick JW et al (2014) Merkel cell carcinoma dependence on Bcl-2 family members for survival. J Invest Dermatol 134(8):2241-2250
5. Wobser M, Voigt H, Eggert AO et al (2007) Bcl-2 expression in rituximab refractory cutaneous B-cell lymphoma. Br J Cancer 96(10):1540-1543
6. Willis SN, Fletcher JI, Kaufmann T et al (2007) Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315(5813):856-859
7. Tse C, Shoemaker AR, Adickes J et al (2008) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68(9):3421-3428
8. Certo M, Del Gaizo Moore V, Nishino M et al (2006) Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9(5):351-365
9. Chen L, Willis SN, Wei A et al (2005) Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17(3):393-403
10. Kim H, Rafiuddin-Shah M, Tu HC et al (2006) Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 8(12):1348-1358
11. Park CM, Bruncko M, Adickes J et al (2008) Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J Med Chem 51(21):6902-6915
12. Chen J, Jin S, Abraham V et al (2011) The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther 10(12):2340-2349
13. Shi J, Zhou Y, Huang HC, Mitchison TJ (2011) Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL. Cancer Res 71(13):4518-4526
14. Ackler S, Mitten MJ, Foster K et al (2010) The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemother Pharmacol 66(5):869-880
15. Gandhi L, Camidge DR, Ribeiro de Oliveira M et al (2011) Phase I study of navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 29(7):909-916
16. Roberts AW, Seymour JF, Brown JR et al (2012) Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 30(5):488-496
17. Rudin CM, Hann CL, Garon EB et al (2012) Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res 18(11):3163-3169
18. Wilson WH, O'Connor OA, Czuczman MS et al (2010) Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 11(12):1149-1159
19. Ackler S, Mitten MJ, Chen J et al (2012) Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo. Br J Pharmacol 167(4):881-891
20. Cleary JM, Lima CM, Hurwitz HI et al (2014) A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors. Invest New Drugs 32(5):937-945
21. Li M, Wang Z, Guo J et al (2014) Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer. Onco Targets Ther. 7:1653-1661
22. CAMPTOSAR (irinotecan hydrochloride injection) (2012) Full prescribing information. Pharmacia and Upjohn Company, New York
23. Clinical Practice Guidelines in Oncology: Colon Cancer, Version 2.2015. National Comprehensive Cancer Network; 2015
24. Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. Cancer Therapy Evaluation Program; March 31, 2003; Publish Date: August 9, 2006
25. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228-247
26. Liu X, Xu W (2014) UGT1A1 28 polymorphisms: a potential pharmacological biomarker of irinotecan-based chemotherapies in colorectal cancer. Pharmacogenomics 15(9):1171-1174